Tezruly is a drug owned by Novitium Pharma Llc. It is protected by 1 US drug patent filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 18, 2042. Details of Tezruly's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11224572 | Stable oral liquid composition of terazosin |
Jan, 2042
(17 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Tezruly is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tezruly's family patents as well as insights into ongoing legal events on those patents.
Tezruly's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tezruly's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 18, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tezruly Generic API suppliers:
Terazosin Hydrochloride is the generic name for the brand Tezruly. 11 different companies have already filed for the generic of Tezruly, with Norvium Bioscience having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tezruly's generic
Alternative Brands for Tezruly
There are several other brand drugs using the same active ingredient (Terazosin Hydrochloride) as Tezruly. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbott |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Terazosin Hydrochloride, Tezruly's active ingredient. Check the complete list of approved generic manufacturers for Tezruly
About Tezruly
Tezruly is a drug owned by Novitium Pharma Llc. Tezruly uses Terazosin Hydrochloride as an active ingredient. Tezruly was launched by Novitium Pharma in 2024.
Approval Date:
Tezruly was approved by FDA for market use on 29 July, 2024.
Active Ingredient:
Tezruly uses Terazosin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Terazosin Hydrochloride ingredient
Dosage:
Tezruly is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1MG BASE/ML | SOLUTION | Discontinued | ORAL |